Question explored with the scientific record
What is the benefit in me prescribing Eylea 8mg injections to patients?
The evidence for Eylea 8 mg is not in these records. The retrieved studies all test the older 2 mg dose, so the benefit of prescribing the higher dose is not supported by the data here.
The studies you have describe the 2 mg version. In wet AMD, fixed 2 mg aflibercept produced better 12-month vision than as-needed dosing, but the gain was modest: about 4.8 more letters than PRN at month 12 [1]. In diabetic macular edema, 2 mg aflibercept improved vision by about 11 letters over 100 weeks in patients without prior anti-VEGF treatment [2]. Over four years, patients averaged about 19 injections and vision was maintained [5]. The 8 mg dose is meant to last longer between injections, but none of these records test that claim.
The safety data here covers the 2 mg dose. In a large Japanese surveillance study of 3,872 patients, adverse events occurred in 5.73% and adverse drug reactions in 2.76% over 36 months [6]. The most common ocular events were macular edema, retinal ischemia, and decreased visual acuity [4]. A meta-analysis found modest retinal nerve fiber layer thinning of about 2.7 micrometers after anti-VEGF injections, with uncertain clinical meaning [3]. The 8 mg dose delivers more drug per injection, which could change the safety profile, but no study here examines that.
My call: the 8 mg dose may reduce injection frequency, but the evidence you have does not show it. Confidence: low, because the retrieval missed the relevant dose entirely.
Sources used 6
-
TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
In a propensity score-matched study of eyes with neovascular AMD, aflibercept given with a fixed regimen produced better 12-month visual acuity outcomes than PRN dosing, with PRN failing noninferiority at Months 8 and 12.
DOI: 10.1097/iae.0000000000002299 -
Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment
This study evaluates the visual and anatomic outcomes of intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-VEGF treatment, demonstrating significant improvements over laser treatment through 100 weeks.
DOI: 10.1016/j.ophtha.2015.11.008 -
The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis
Intravitreal anti-VEGF injections cause transient intraocular pressure (IOP) spikes that generally normalize within days, whereas dexamethasone implants produce longer-lasting IOP elevation; retinal nerve fiber layer (RNFL) thinning with anti-VEGF appears modest and its clinical…
DOI: 10.1038/s41598-020-70269-7 -
Aflibercept im klinischen Alltag: die AURIGA-Studie
In the German AURIGA cohort of treatment-naive patients with macular edema from retinal vein occlusion, intravitreal aflibercept 2 mg produced rapid visual and anatomic improvement that was largely maintained over 24 months despite reduced injection frequency.
DOI: 10.1007/s00347-024-02051-3 -
Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting
A retrospective, real-world, single-center study assessing four-year visual and anatomical outcomes of intravitreal aflibercept for neovascular age-related macular degeneration, showing maintained or improved vision and reduced central subfield thickness with a mean of ~19 injec…
DOI: 10.1177/1120672120938565 -
Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration
In 3,872 Japanese patients with nAMD, 36-month intravitreal aflibercept surveillance showed AEs in 5.73%, ADRs in 2.76%, and numerically improved BCVA/CRT, indicating acceptable real-world tolerability and effectiveness.
DOI: 10.1038/s41598-023-37584-1